Corvus Pharmaceuticals (CRVS) Assets Average (2016 - 2026)
Corvus Pharmaceuticals (CRVS) posted quarterly Assets Average of $162.2 million for Q1 2026, up 152.69% year-over-year from $64.2 million in Q1 2025, and up 113.94% quarter-over-quarter from $75.8 million in Q4 2025.
Corvus Pharmaceuticals (CRVS) Assets Average (2016 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Assets Average history runs 11 years deep, the most recent figure standing at $162.2 million for Q1 2026.
- In Q1 2026, Assets Average rose 152.69% year-over-year to $162.2 million; the TTM figure through Mar 2026 stood at $162.2 million (up 152.69% YoY), while the FY2025 annual figure was $70.0 million, up 22.34% from the prior year.
- Assets Average for Q1 2026 stood at $162.2 million, up from $75.8 million in the prior quarter.
- The five-year high for Assets Average was $162.2 million in Q1 2026, with the low at $42.8 million in Q1 2024.
- The 5-year median for Assets Average is $64.2 million (2025), against an average of $74.7 million.
- The sharpest annual moves came in 2023 and 2026: Assets Average tumbled 40.03% in 2023, then surged 152.69% in 2026.
- Corvus Pharmaceuticals' Assets Average stood at $74.3 million in 2022, then sank by 34.39% to $48.7 million in 2023, then jumped by 31.0% to $63.9 million in 2024, then grew by 18.69% to $75.8 million in 2025, then jumped by 113.94% to $162.2 million in 2026.
- Business Quant data shows CRVS's Assets Average at $162.2 million in Q1 2026, $75.8 million in Q4 2025, and $85.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Corvus Pharmaceuticals | 1.25 Bn | 1.04 Bn | - | 246.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 246.23 Mn |
| Mar 31, 2026 | 162.16 Mn |
| Dec 31, 2025 | 75.80 Mn |
| Sep 30, 2025 | 84.97 Mn |
| Jun 30, 2025 | 74.45 Mn |
| Mar 31, 2025 | 64.17 Mn |
| Dec 31, 2024 | 63.86 Mn |
| Sep 30, 2024 | 61.69 Mn |
| Jun 30, 2024 | 52.32 Mn |
| Mar 31, 2024 | 42.82 Mn |
| Dec 31, 2023 | 48.75 Mn |
| Sep 30, 2023 | 54.99 Mn |
| Jun 30, 2023 | 58.12 Mn |
| Mar 31, 2023 | 63.22 Mn |
| Dec 31, 2022 | 74.29 Mn |
| Sep 30, 2022 | 86.44 Mn |
| Jun 30, 2022 | 96.92 Mn |
| Mar 31, 2022 | 105.37 Mn |
| Dec 31, 2021 | 114.39 Mn |
| Sep 30, 2021 | 114.36 Mn |